Nitronal (Glyceryl Trinitrate)

Glyceryl trinitrate acts as a donor of nitric oxide. The released nitric oxide activates guanylate cyclase in vascular smooth muscle, raising cyclic GMP levels. Elevated cyclic GMP causes smooth‑muscle relaxation, leading to dilation of veins, arteries and coronary vessels, which reduces cardiac preload and afterload.

The specific dose of Nitronal is determined by the treating physician based on the patient’s clinical condition, blood pressure response and therapeutic goals. Dosing is individualized, and the prescriber will set the infusion rate and any necessary adjustments.

Safety data for glyceryl trinitrate in pregnancy and lactation are limited. The drug should be used only if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To order Nitronal, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Nitronal belongs to the organic nitrate class, providing rapid onset of vasodilation. Compared with oral nitrates, the intravenous form offers faster blood‑level control, which is advantageous in emergencies. It differs from calcium‑channel blockers or beta‑blockers, which act through distinct mechanisms and have different side‑effect profiles.

Nitronal should be stored below 25 °C in its original container, protected from light and moisture. The solution must be kept in a secure, temperature‑controlled environment and inspected for particulate matter before use. Do not freeze or shake the vial.

Nitronal is given by intravenous infusion. The solution is typically diluted in a compatible carrier fluid and administered through a controlled infusion pump. Administration is performed by trained healthcare personnel, with continuous monitoring of blood pressure, heart rate and clinical response.

The most serious adverse events include severe hypotension that may require emergency intervention, methemoglobinemia leading to impaired oxygen delivery, and rare allergic reactions such as anaphylaxis. Prompt recognition and supportive measures are essential if these events occur.

Nitronal is contraindicated in patients with known hypersensitivity to glyceryl trinitrate or other organic nitrates, in those with severe anemia, increased intracranial pressure, or in patients who have taken phosphodiesterase‑5 inhibitors within the previous 24 hours due to the risk of profound hypotension.